fbpx
Business & FinanceHealth

Reuters exclusively reports Lonza sets new goal to make Moderna COVID-19 vaccine ingredients

Reuters exclusively reported that Lonza aims to speed completion of two commercial production lines for Moderna Inc’s trial COVID-19 vaccine so manufacturing could start four to six weeks earlier than planned if the project is successful. Moderna, which enlisted Lonza in May in a 10-year manufacturing contract, is racing with 100-plus other vaccine projects, having last week dosed initial participants in a 600-patient study.

Article Tags
Topics of Interest: Business & FinanceHealth
Type: Reuters Best
Sectors: Equities
Regions: Europe / Middle East / Africa
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Sign up for email updates

Subscribe
Sign up for email updates